Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Amgen Inc.‘s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company ...

Amgen Inc.'s stock took a hit Monday after the biotechnology giant lost a bull, amid concerns that prices already reflect investor optimism over the obesity drug candidate, leaving more downside ...

What do Amgen, Biogen, and Takeda have in common? Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their ...

AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...